Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Myeloproliferative Neoplasms Specialty Channel

Myeloproliferative Neoplasms
Specialty Channel
News
Eltrombopag and Cyclosporin A Demonstrate Beneficial Outcomes as Frontline Treatment for Patients With Severe Aplastic Anemia
03/18/2024

Jordan Kadish

Jordan Kadish
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR...
03/18/2024
Oncology
Anthony Hunter, MD
Videos
Choosing Interferon Treatment for Patients With Myeloproliferative Neoplasms
10/16/2023

Featuring Anthony Hunter, MD

Featuring Anthony Hunter, MD
Anthony Hunter, MD, discusses the role of interferon regimens for patients with myeloproliferative neoplasms, including polycythemia vera and essential thrombocythemia.
Anthony Hunter, MD, discusses the role of interferon regimens for patients with myeloproliferative neoplasms, including polycythemia vera and essential thrombocythemia.
Anthony Hunter, MD, discusses...
10/16/2023
Oncology
Quiz
Hydroxyurea Dosage and Management for Patients With PV
09/25/2023
True or False: Results of a retrospective, real-world analysis determined that some patients with chronic myeloproliferative neoplasm polycythemia vera received underdosed hydroxyurea, which led to lower complete response and toxicity rates,...
True or False: Results of a retrospective, real-world analysis determined that some patients with chronic myeloproliferative neoplasm polycythemia vera received underdosed hydroxyurea, which led to lower complete response and toxicity rates,...
True or False: Results of a...
09/25/2023
Oncology
News
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio as Potential Minor Criteria for Polycythemia Vera Diagnosis
08/22/2023

Amber Denham

Amber Denham
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio...
08/22/2023
Oncology
News
Optimizing Hydroxyurea Management Among Patients With Polycythemia Vera
08/09/2023

Amber Denham

Amber Denham
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea...
08/09/2023
Oncology
News
Alternative Dosing Regimen of Ropeginterferon Alfa-2b Demonstrates High Efficacy, Tolerability Among Patients With Polycythemia Vera
07/14/2023

Gina Tomaine

Gina Tomaine
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of...
07/14/2023
Oncology
News
Ruxolitinib Treatment Effective, Safe for Patients With Newly Diagnosed Polycythemia Vera
05/05/2023

Gina Tomaine 

Gina Tomaine 
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to...
05/05/2023
Oncology
John Mascarenhas, MD
Videos
Recent Advancements in Clinical Development for the Treatment of Myelofibrosis
05/04/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies conference, New York, John Mascarenhas, MD, discussed recent advancements in clinical developments for the treatment of myeloproliferative neoplasms, specifically myelofibrosis,...
At the 2023 Great Debates & Updates in Hematologic Malignancies conference, New York, John Mascarenhas, MD, discussed recent advancements in clinical developments for the treatment of myeloproliferative neoplasms, specifically myelofibrosis,...
At the 2023 Great Debates &...
05/04/2023
Oncology
Claire Harrison, MD
Videos
Second-Line Therapy for Patients With Polycythemia Vera: A Review of Data on Ruxolitinib
05/04/2023
In the final part of an expert roundtable series, Claire Harrison, MD, leads a panel discussion reviewing data on second-line therapies, particularly ruxolitinib, for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and...
In the final part of an expert roundtable series, Claire Harrison, MD, leads a panel discussion reviewing data on second-line therapies, particularly ruxolitinib, for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and...
In the final part of an expert...
05/04/2023
Oncology
Claire Harrison, MD
Videos
How to Determine When First-Line Therapy for Polycythemia Vera is Failing
05/04/2023
In part 3 of an expert roundtable series, Claire Harrison, MD, leads a panel discussion on how to determine when first-line polycythemia vera therapy is failing with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 3 of an expert roundtable series, Claire Harrison, MD, leads a panel discussion on how to determine when first-line polycythemia vera therapy is failing with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 3 of an expert...
05/04/2023
Oncology
Claire Harrison, MD
Videos
Aims of Treatment and Choice of First-Line Therapy for Patients With Polycythemia Vera
05/04/2023
In part 2 of an expert roundtable series, Claire Harrison, MD, leads a discussion on the aims of treatment and choice of first-line therapy for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 2 of an expert roundtable series, Claire Harrison, MD, leads a discussion on the aims of treatment and choice of first-line therapy for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 2 of an expert...
05/04/2023
Oncology

Advertisement

News

News
Eltrombopag and Cyclosporin A Demonstrate Beneficial Outcomes as Frontline Treatment for Patients With Severe Aplastic Anemia
03/18/2024

Jordan Kadish

Jordan Kadish
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR...
03/18/2024
Oncology
News
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio as Potential Minor Criteria for Polycythemia Vera Diagnosis
08/22/2023

Amber Denham

Amber Denham
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio...
08/22/2023
Oncology
News
Optimizing Hydroxyurea Management Among Patients With Polycythemia Vera
08/09/2023

Amber Denham

Amber Denham
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea...
08/09/2023
Oncology
News
Alternative Dosing Regimen of Ropeginterferon Alfa-2b Demonstrates High Efficacy, Tolerability Among Patients With Polycythemia Vera
07/14/2023

Gina Tomaine

Gina Tomaine
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of...
07/14/2023
Oncology
News
Ruxolitinib Treatment Effective, Safe for Patients With Newly Diagnosed Polycythemia Vera
05/05/2023

Gina Tomaine 

Gina Tomaine 
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to...
05/05/2023
Oncology
News
Momelotinib Improved Anemia Measures, Spleen Response, and Overall Safety Among Patients With Myelofibrosis
04/21/2023

Jordan Kadish

Jordan Kadish
According to a phase 3 trial, momelotinib, a first-class JAK1 and JAK2 inhibitor, improved anemia measures, spleen response, and overall safety among patients with myelofibrosis compared to other JAK inhibitors.
According to a phase 3 trial, momelotinib, a first-class JAK1 and JAK2 inhibitor, improved anemia measures, spleen response, and overall safety among patients with myelofibrosis compared to other JAK inhibitors.
According to a phase 3 trial,...
04/21/2023
Oncology
News
Low-Intensity Regimens for Sickle Cell Disease Transplantation Associated With Risk of Secondary Neoplasms
03/13/2023

Jordan Kadish

Jordan Kadish
Low-intensity regimens for sickle cell disease transplantations were associated with a higher risk of secondary neoplasms, including leukemia and myelodysplastic syndromes.
Low-intensity regimens for sickle cell disease transplantations were associated with a higher risk of secondary neoplasms, including leukemia and myelodysplastic syndromes.
Low-intensity regimens for...
03/13/2023
Oncology
Conference Coverage
Ropeginterferon Alfa-2b Yielded Higher Hematologic and Molecular Response Rates Among Patients With Low-Risk vs High-Risk Polycythemia Vera
02/27/2023

Jordan Kadish

Jordan Kadish
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that...
02/27/2023
Oncology
News
Increased Likelihood of Blood Clots in Patients With Non-Proliferative CBC Thrombosis Myeloproliferative Neoplasms
02/27/2023

Jordan Kadish

Jordan Kadish
A study found that patients with non-proliferative CBC thrombosis MPNs and driver mutations with non-splanchnic involvement have an increased risk for recurrent blood clots and progression of the disorder than those with splanchnic...
A study found that patients with non-proliferative CBC thrombosis MPNs and driver mutations with non-splanchnic involvement have an increased risk for recurrent blood clots and progression of the disorder than those with splanchnic...
A study found that patients with...
02/27/2023
Oncology
News
Cytoreduction and JAK Inhibitors Associated With Fewer Thrombotic Events in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis
09/30/2022

Gina Tomaine

Gina Tomaine
Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombotic events in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombotic events in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
Both conventional cytoreduction...
09/30/2022
Oncology

Interactive Features

Quiz
Hydroxyurea Dosage and Management for Patients With PV
09/25/2023
True or False: Results of a retrospective, real-world analysis determined that some patients with chronic myeloproliferative neoplasm polycythemia vera received underdosed hydroxyurea, which led to lower complete response and toxicity rates,...
True or False: Results of a retrospective, real-world analysis determined that some patients with chronic myeloproliferative neoplasm polycythemia vera received underdosed hydroxyurea, which led to lower complete response and toxicity rates,...
True or False: Results of a...
09/25/2023
Oncology
Quiz
Cytoreduction and JAK Inhibitors in Patients With Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis
11/30/2022
True or False: Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
True or False: Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
True or False: Both conventional...
11/30/2022
Oncology
Quiz
Quiz: Cytogenic Response Rate of Pemigatinib in Myeloid/Lymphoid Neoplasms Harboring an FGFR1 Arrangement
09/02/2022
The FDA granted approval to pemigatinib to treat adult patients with relapsed or refractory myeloid/lymphoid neoplasms and an FGFR1 rearrangement. In the phase 2 trial which led to the approval, what was the complete cytogenetic response rate...
The FDA granted approval to pemigatinib to treat adult patients with relapsed or refractory myeloid/lymphoid neoplasms and an FGFR1 rearrangement. In the phase 2 trial which led to the approval, what was the complete cytogenetic response rate...
The FDA granted approval to...
09/02/2022
Oncology
idea
Test Your Knowledge
Quiz: Do Antiplatelet, Anticoagulation Therapies Increase Bleeding Risk for MPNs?
02/01/2022
True or false: A retrospective study found antiplatelet and anticoagulation therapies do not increase the risk of bleeding events in patients with MPNs.
True or false: A retrospective study found antiplatelet and anticoagulation therapies do not increase the risk of bleeding events in patients with MPNs.
True or false: A retrospective...
02/01/2022
Oncology
Question marks
Quiz
Quiz: Sotatercept for Anemic Patients With MPN-Associated MF
01/20/2022
True or false: A phase 2 study found sotatercept to be unsafe and ineffective for anemic patients with MPN-associated MF.
True or false: A phase 2 study found sotatercept to be unsafe and ineffective for anemic patients with MPN-associated MF.
True or false: A phase 2 study...
01/20/2022
Oncology
writing
Test Your Knowledge
Quiz: Pulmonary Hypertension in Patients With MPNs
01/06/2022
True or false: Findings from a single-center retrospective study investigated the prognostic implication of pulmonary hypertension (PH) in a high-risk MPNs patient population and found PH is associated with worse outcomes.
True or false: Findings from a single-center retrospective study investigated the prognostic implication of pulmonary hypertension (PH) in a high-risk MPNs patient population and found PH is associated with worse outcomes.
True or false: Findings from a...
01/06/2022
Oncology
?
Test Your Knowledge
Quiz: Are DOACs Associated With High Bleeding Rates in MPNs?
12/17/2021
True or false: DOAC’s are associated with high bleeding rates in patients with MPNs.
True or false: DOAC’s are associated with high bleeding rates in patients with MPNs.
True or false: DOAC’s are...
12/17/2021
Oncology
Computer
Test Your Knowledge
Quiz: Does This Inhibitor Therapy Yield Safety in Portal Hypertension MPNs?
12/16/2021
True or false: JAK inhibitor therapy is safe and effective in patients with MPNs complicated by PT without underlying ST.
True or false: JAK inhibitor therapy is safe and effective in patients with MPNs complicated by PT without underlying ST.
True or false: JAK inhibitor...
12/16/2021
Oncology
Test Your Knowledge
Quiz: Mutation Identified as High-Risk Bleeding Factor in MPN
11/29/2021
Which of the following mutations is associated with a higher risk of bleeding in adult patients with MPN?
Which of the following mutations is associated with a higher risk of bleeding in adult patients with MPN?
Which of the following mutations...
11/29/2021
Oncology
qq
Test Your Knowledge
Quiz: Which Mutation Was Identified as High-Risk Bleeding Factor in MPN?
11/11/2021
Which of the following mutations was identified as a high-risk bleeding factor in MPN?
Which of the following mutations was identified as a high-risk bleeding factor in MPN?
Which of the following mutations...
11/11/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Eltrombopag and Cyclosporin A Demonstrate Beneficial Outcomes as Frontline Treatment for Patients With Severe Aplastic Anemia
03/18/2024

Jordan Kadish

Jordan Kadish
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.
According to the phase 2 SOAR...
03/18/2024
Oncology
News
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio as Potential Minor Criteria for Polycythemia Vera Diagnosis
08/22/2023

Amber Denham

Amber Denham
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.
Neutrophil-to-lymphocyte ratio...
08/22/2023
Oncology
News
Optimizing Hydroxyurea Management Among Patients With Polycythemia Vera
08/09/2023

Amber Denham

Amber Denham
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea...
08/09/2023
Oncology
News
Alternative Dosing Regimen of Ropeginterferon Alfa-2b Demonstrates High Efficacy, Tolerability Among Patients With Polycythemia Vera
07/14/2023

Gina Tomaine

Gina Tomaine
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.
A new dosing regimen of...
07/14/2023
Oncology
News
Ruxolitinib Treatment Effective, Safe for Patients With Newly Diagnosed Polycythemia Vera
05/05/2023

Gina Tomaine 

Gina Tomaine 
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.
Ruxolitinib therapy was found to...
05/05/2023
Oncology
News
Momelotinib Improved Anemia Measures, Spleen Response, and Overall Safety Among Patients With Myelofibrosis
04/21/2023

Jordan Kadish

Jordan Kadish
According to a phase 3 trial, momelotinib, a first-class JAK1 and JAK2 inhibitor, improved anemia measures, spleen response, and overall safety among patients with myelofibrosis compared to other JAK inhibitors.
According to a phase 3 trial, momelotinib, a first-class JAK1 and JAK2 inhibitor, improved anemia measures, spleen response, and overall safety among patients with myelofibrosis compared to other JAK inhibitors.
According to a phase 3 trial,...
04/21/2023
Oncology
News
Low-Intensity Regimens for Sickle Cell Disease Transplantation Associated With Risk of Secondary Neoplasms
03/13/2023

Jordan Kadish

Jordan Kadish
Low-intensity regimens for sickle cell disease transplantations were associated with a higher risk of secondary neoplasms, including leukemia and myelodysplastic syndromes.
Low-intensity regimens for sickle cell disease transplantations were associated with a higher risk of secondary neoplasms, including leukemia and myelodysplastic syndromes.
Low-intensity regimens for...
03/13/2023
Oncology
Conference Coverage
Ropeginterferon Alfa-2b Yielded Higher Hematologic and Molecular Response Rates Among Patients With Low-Risk vs High-Risk Polycythemia Vera
02/27/2023

Jordan Kadish

Jordan Kadish
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.
A phase 3 study found that...
02/27/2023
Oncology
News
Increased Likelihood of Blood Clots in Patients With Non-Proliferative CBC Thrombosis Myeloproliferative Neoplasms
02/27/2023

Jordan Kadish

Jordan Kadish
A study found that patients with non-proliferative CBC thrombosis MPNs and driver mutations with non-splanchnic involvement have an increased risk for recurrent blood clots and progression of the disorder than those with splanchnic...
A study found that patients with non-proliferative CBC thrombosis MPNs and driver mutations with non-splanchnic involvement have an increased risk for recurrent blood clots and progression of the disorder than those with splanchnic...
A study found that patients with...
02/27/2023
Oncology
News
Cytoreduction and JAK Inhibitors Associated With Fewer Thrombotic Events in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis
09/30/2022

Gina Tomaine

Gina Tomaine
Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombotic events in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombotic events in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.
Both conventional cytoreduction...
09/30/2022
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement